Navigation Links
BIDMC researcher receives Young Investigator Award from Prostate Cancer Foundation
Date:6/30/2010

BOSTON Akash Patnaik, MD, PhD, a physician-scientist in the Hematology/Oncology Divison at Beth Israel Deaconess Medical Center (BIDMC) and Instructor of Medicine at Harvard Medical School has received a Young Investigator Award from The Prostate Cancer Foundation (PCF). The three-year $225,000 award, one of 21 made to young scientists from across the U.S. and Canada, is designed to encourage the most innovative minds in cancer research to focus their careers on prostate cancer.

Patnaik's research focuses on the relationship between diet-induced obesity /associated metabolic abnormalities and prostate cancer. With the PCF funding, he will investigate the molecular mechanisms that link the metabolic abnormalities of obesity to poor outcomes in prostate cancer patients.

"Hormones, such as insulin, are increased in obese patients and are known to drive the progression and survival of prostate cancer cells," Patnaik explains. "Recent epidemiological studies have shown that men who are treated with metformin, a medication prescribed for Type 2 diabetes, have a reduced risk of prostate cancer." Patnaik will evaluate the anti-cancer mechanism and efficacy of metformin and related medications to prolong overall survival of patients with advanced prostate cancer.

"Obesity is strongly associated with poor prostate cancer prognosis," notes Lewis Cantley, PhD, Patnaik's postdoctoral research mentor and Director of BIDMC's Cancer Center and William Bosworth Castle Professor of Medicine at Harvard Medical School. "Dr. Patnaik's investigations promise to provide us with a better understanding of the molecular events that drive obesity-induced cancers, and provide a rationale for a new metabolic treatment strategy for advanced prostate-cancer patients."

Patnaik will utilize a "co-clinical trial paradigm" to identify novel targeted therapies for advanced prostate cancer patients. In this way he will assess the responses of genetically engineered mouse models to specific cancer drugs, and then use this information to stratify patients into specific treatment arms, based on patients' cancer mutations and their individual metabolic profiles.


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers suggest new paradigm for breast cancer screening
2. Of lice and man: Researchers sequence human body louse genome
3. AcademyHealth honors leading health services researchers
4. UCLA researchers, US military collaborate to open center for traumatic brain injury
5. Texas A&M researcher explains how embryo fights retroviral infection
6. UC San Diego researcher awarded $5.3 million for breast cancer survivorship study
7. UCSD researchers receive $2.5 million in new stem cell grants
8. Researchers find key to getting estrogens benefits without cancer risk
9. Mount Sinai researchers find structural basis for incidence of skin cancers in a genetic disorder
10. WSU researchers find mothers of children with autism pay price in workplace
11. Free Resources from EBSCO Publishing Providing Useful Information to Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... of Justice jointly issued a letter to withdraw previous guidance issued ... their gender identity. The guidance issued in May 2016 by the Obama Administration ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... 23, 2017 , ... ERT, a global data and technology ... Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite ... in part to an array of circumstances including the use of multiple data ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology: